Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

126
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
126
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

684
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
684
Drug Therapy01:28

Drug Therapy

195
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
195
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.2K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.2K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

377
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
377

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline working memory was associated with improvement in psychological quality of life in patients with persistent depressive symptoms: a prospective observational study.

Frontiers in psychiatry·2026
Same author

A preliminary cross-sectional study of bipolarity and primary pharmacotherapy in long-term stable patients with major depressive disorder.

International journal of bipolar disorders·2026
Same author

Pharmacological treatment of schizophrenia: Japanese Expert Consensus 2025.

Schizophrenia (Heidelberg, Germany)·2026
Same author

Factors associated with social functioning by relapse frequency in Japanese outpatients with schizophrenia: the Multicenter Treatment Survey and Assessments for Schizophrenia in Psychiatric Clinics (MUSASI).

Psychological medicine·2026
Same author

Analysis of Causal Factors to Acute Malnutrition Among Children Under the Age of Five in West Nile, Uganda.

Food science & nutrition·2026
Same author

Antidepressant Prescribing Patterns At Initial Visits for Patients With Mild Depression: A Retrospective Study.

Pharmacopsychiatry·2026
Same journal

[The Current Issues of Crime Victim Support from a Clinical Point of View].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica·2019
Same journal

[The Role of Psychiatrists as Personal Support Specialists].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica·2019
Same journal

[Historical Re-evaluation of the System of Sending Psychiatrists to Okinawa and the Activities of the Japanese Society of Psychiatry and Neurology].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica·2019
Same journal

[Background of Okinawa's Acceptance of Dispatched Physicians and Its Current Status].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica·2019
Same journal

[Medical Dispatch to Okinawa and following Period].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica·2019
Same journal

[The Situation of Psychiatric Medicine and the System of Dispatching Medical Doctors Half a Century Ago in Okinawa].

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica·2019
See all related articles

Related Experiment Video

Updated: Dec 20, 2025

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:36

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

141

[Changes in pharmacotherapy for depression].

Koichiro Watanabe1

  • 1Department of Neuropsychiatry, School of Medicine, Keio University.

Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica
|January 14, 2011
PubMed
Summary
This summary is machine-generated.

Antidepressant treatment for depression has become more complex since 1999. Key challenges include adherence, side effects like fatigue, and distinguishing depression from bipolar disorder, necessitating nuanced clinical approaches.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

440
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.3K

Related Experiment Videos

Last Updated: Dec 20, 2025

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:36

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

141
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

440
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.3K

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Context:

  • Pharmacotherapy, introduced with fluvoxamine in 1999, was central to depression treatment.
  • Treatment goals have shifted towards remission and recovery, increasing adherence challenges.
  • The distinction between depression and bipolar disorder has become a significant clinical debate.

Purpose:

  • To review the evolving landscape of depression pharmacotherapy.
  • To highlight challenges in antidepressant treatment adherence and side effect management.
  • To examine current treatment guidelines for depression.

Summary:

  • Antidepressant effectiveness and adherence issues have emerged since 1999.
  • Sleepiness and fatigue are common side effects; distinguishing sedative from non-sedative antidepressants is crucial.
  • For mild depression, non-pharmacological interventions promoting resilience are recommended, contrasting with moderate depression where pharmacotherapy remains first-line.

Impact:

  • Clinicians must navigate complex treatment decisions, balancing pharmacotherapy with non-pharmacological approaches.
  • Understanding side effect profiles and patient adherence is critical for effective depression management.
  • The evolving understanding of depression necessitates updated clinical strategies and guideline adherence.